VHL and hypoxia signaling: Beyond HIF in cancer

Jing Zhang, Qing Zhang

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Von Hippel-Lindau (VHL) is an important tumor suppressor that is lost in the majority of clear cell carcinoma of renal cancer (ccRCC). Its regulatory pathway involves the activity of E3 ligase, which targets hypoxia inducible factor α (including HIF1α and HIF2α) for proteasome degradation. In recent years, emerging literature suggests that VHL also possesses other HIF-independent functions. This review will focus on VHL-mediated signaling pathways involving the latest identified substrates/binding partners, including N-Myc downstream-regulated gene 3 (NDRG3), AKT, and G9a, etc., and their physiological roles in hypoxia signaling and cancer. We will also discuss the crosstalk between VHL and NF-κB signaling. Lastly, we will review the latest findings on targeting VHL signaling in cancer.

Original languageEnglish (US)
Article number35
JournalBiomedicines
Volume6
Issue number1
DOIs
StatePublished - Mar 1 2018
Externally publishedYes

Keywords

  • Hypoxia
  • VHL
  • ccRCC

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'VHL and hypoxia signaling: Beyond HIF in cancer'. Together they form a unique fingerprint.

  • Cite this